← Patent-cliff monitor small molecule WEGOVY SEMAGLUTIDE
Loss of exclusivity February 2041 latest FDA-listed patent expiry
Company NOVO NORDISK INC
Drug detail Brand name WEGOVY Active ingredient SEMAGLUTIDE Strength 0.5MG/0.5ML (0.5MG/0.5ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval June 2021 Marketing status RX
Listed patents Patent Expires Type 11318191 February 2041 product 11478533 May 2040 use U-3861 10888605 August 2038 product 12214017 August 2038 product 11752198 August 2038 product 9764003 June 2033 use U-3161 8129343 December 2031 substance, product 8536122 March 2026 substance, product
Regulatory exclusivity Code Expires I-973 August 2028 I-935 March 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.